Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03339206 · ClinicalTrials.gov registry record · NA
Enhancing Source Credibility in Tobacco Regulatory Communications
A NA study of Cigarette Smoking Behavior, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 845
- Enrollment target
- 1
- Study location
NCT03339206: Completed NA study of Cigarette Smoking Behavior, sponsored by UNC Lineberger Comprehensive Cancer Center.
NCT03339206 is a NA study of Cigarette Smoking Behavior that has completed, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 845 participants, roughly in line with the 777-participant average among 4 other Cigarette Smoking Behavior trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03339206, a NA study of Cigarette Smoking Behavior, has completed, sponsored by UNC Lineberger Comprehensive Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 845 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will assess the impact of cigarette constituent messages with and without FDA source and quit information in a randomized controlled trial. The investigators hypothesize that cigarette constituent messages will increase intention to quit compared to messages about littering cigarettes (the control). The investigators also hypothesize that constituent messages that include FDA source and quit information will increase intention to quit compared to messages without that information.
Primary Outcome
Average quit intention score measured at 16 days by survey. Quit intention measured with 3 questions, the final quit intention score is a mean of the response to the 3 questions, on a scale of 1 to 4, where 1 indicates low intention to quit, and 4 indicates a high intention to quit.
Conditions Studied
Interventions
- BEHAVIORAL Constituent message with FDA and quitline
- BEHAVIORAL Constituent message without FDA and quitline
- BEHAVIORAL Littering message (Control)
Study Locations (1)
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 845 participants |
| Start Date | 2017-10-10 |
| Est. Completion | 2018-05-23 |
| Phase | NA |
What the finished NCT03339206 record still lists
NCT03339206 is an interventional study that assigns participants to a tested intervention. The registered 845 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 777-participant average among 4 other Cigarette Smoking Behavior trials with a reported enrollment target.
The record links to 1 condition, with Cigarette Smoking Behavior appearing as the primary indexed condition, and to 3 interventions - of which Constituent message with FDA and quitline is the first listed.
NCT03339206 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT03339206 about?
NCT03339206 is a clinical study titled "Enhancing Source Credibility in Tobacco Regulatory Communications". This study will assess the impact of cigarette constituent messages with and without FDA source and quit information in a randomized controlled trial. The investigators hypothesize that cigarette constituent messages will increase intention to quit compared to messages about littering cigarettes (th...
What is the current status of trial NCT03339206?
This trial is currently completed. It is a NA study. The enrollment target is 845 participants. The study started on 2017-10-10. Estimated completion is 2018-05-23.
What conditions does trial NCT03339206 study?
This clinical trial studies the following conditions: Cigarette Smoking Behavior.
What interventions are being tested in trial NCT03339206?
The interventions under investigation include: Constituent message with FDA and quitline (BEHAVIORAL), Constituent message without FDA and quitline (BEHAVIORAL), Littering message (Control) (BEHAVIORAL).
Who is sponsoring clinical trial NCT03339206?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03339206 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cigarette Smoking Behavior
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Catalyzing Cigarette Smoking Cessation Through Harm Reduction Sampling Among People Unmotivated to Quit
RECRUITING · NA
-
Effect of Flavored on!® Nicotine Pouch Products on Smoking Behaviors: a SMART Study
RECRUITING · NA
-
An Experimental Evaluation of Menthol-Flavored Tobacco Accessories
ACTIVE NOT RECRUITING · NA
-
Project RESIST: Increasing Resistance to Tobacco Marketing Among Young Adult Sexual Minority Women Using Inoculation Message Approaches
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02757859 · 845 participants · NA
High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery
- NCT06747949 · 844 participants · Phase 3
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
- NCT06439979 · 843 participants · NA
Rural Adult and Youth Sun Protection Study
- NCT07142408 · 848 participants · Phase 3
The Effect of Bacterial Decolonization Before Skin Cancer Surgery on Infection Rate of Lower Extremity Wounds Left Open to Heal
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI